Overview

DAS181 for STOP COVID-19

Status:
Withdrawn
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ansun Biopharma, Inc.